Does Rallies show 13F holders for CELC?

Yes. Rallies tracks hedge fund and 13F ownership data for CELC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CELC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CELC. It does not provide personalized investment advice.

CELC (Celcuity Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Celcuity Inc. Common Stock (CELC) is a publicly traded Healthcare sector company. As of May 21, 2026, CELC trades at $138.67 with a market cap of $6.45B and a P/E ratio of -36.79. CELC moved +7.15% today. Year to date, CELC is +35.20%; over the trailing twelve months it is +1217.75%. Its 52-week range spans $7.58 to $151.02. Analyst consensus is strong buy with an average price target of $169.88. Rallies surfaces CELC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CELC stock?

Hedge funds tracked by Rallies that own CELC include Orbimed Advisors, Polen Capital, Farallon Capital, and Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Celcuity Inc. Common Stock.

CELC Key Metrics

Key financial metrics for CELC
Metric	Value
Price	$138.67
Market Cap	$6.45B
P/E Ratio	-36.79
EPS	$-3.79
Dividend Yield	0.00%
52-Week High	$151.02
52-Week Low	$7.58
Volume	506
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-177.04M
Gross Margin	0.00%

Top Hedge Funds Holding CELC

Orbimed Advisors holds 85.66K shares of CELC, changed +1.96% as of Dec 31, 2025.
Polen Capital holds 17.18K shares of CELC, changed +268.69% as of Mar 31, 2026.
Farallon Capital holds 4.00K shares of CELC, changed +0.00% as of Mar 31, 2026.
Mangrove Partners holds 2.68K shares of CELC, changed +0.00% as of Mar 31, 2026.

Latest CELC News

Celcuity’s Phase 3 Trial Shows PFS Gains, FDA Sets July 17 PDUFA — May 14, 2026
Celcuity Expands VIKTORIA-2 Trial to 1,180 Patients and Files Subcutaneous Patent — May 14, 2026
Celcuity slips after biotech-run surge as traders lock in gains — May 5, 2026
Celcuity surges as Phase 3 VIKTORIA-1 breast-cancer trial hits primary endpoint — May 4, 2026
Celcuity’s Gedatolisib Triplet Yields Clinically Meaningful PFS Boost in PIK3CA Mutant Cohort — May 1, 2026

Recent CELC Insider Trades

Dalvey David sold 25.00K (~$3.52M) on May 4, 2026.
Buller Richard E sold 1.29K (~$176.59K) on May 4, 2026.
Buller Richard E sold 550 (~$76.45K) on May 4, 2026.

CELC Analyst Consensus

9 analysts cover CELC: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $169.88.

Common questions about CELC

Who owns CELC stock?: Hedge funds tracked by Rallies that own CELC include Orbimed Advisors, Polen Capital, Farallon Capital, and Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Celcuity Inc. Common Stock.
Does Rallies show 13F holders for CELC?: Yes. Rallies tracks hedge fund and 13F ownership data for CELC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CELC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CELC. It does not provide personalized investment advice.